To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

January 13, 2023

Study Completion Date

January 18, 2023

Conditions
Postherpetic Neuralgia
Interventions
DRUG

SR419

SR419 capsule

Trial Locations (13)

Unknown

PARC Clinical Research, Royal Adelaide Hospital, Adelaide

PARATUS Clinical Research Brisbane, Brisbane

PARATUS Clinical Research Canberra, Canberra

Genesis Research Services, Sydney

PARATUS Clinical Research Western Sydney, Sydney

China-Japan Friendship Hospital, Beijing

Peking University Third Hospital, Beijing

Dermatology Hospital of Southern Medical University, Guangzhou

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

The First Affiliated Hospital of Nanchang University, Nanchang

Nanyang First People's Hospital, Nanyang

Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen

The Second Hospital of Tianjin Medical University, Tianjin

All Listed Sponsors
lead

Shanghai SIMR Biotechnology Co., Ltd.

INDUSTRY